Anthracyclines in breast cancer: Therapy and issues of toxicity

Breast

Volumn 10, Issue SUPPL. 2, 2001, Pages 8-15

  Verrill, M ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CITRIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; LIPOSOME; METHOTREXATE; PACLITAXEL; PACLITAXEL DERIVATIVE; PLATINUM DERIVATIVE; RAZOXANE; SEROTONIN 3 ANTAGONIST; TRASTUZUMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DYSESTHESIA; FEMALE; FOOT DISEASE; GASTROINTESTINAL DISEASE; HAND DISEASE; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HUMAN; KAPOSI SARCOMA; LEUKEMIA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; OVARY METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN;

EID: 0034994440     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(01)80002-3     Document Type: Article

References (42)

1. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance
2. L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives
3. A comparison of the lethal and kinetic effects of doxorubicin and 4′-epi-doxorubicin in vitro
4. Interaction of some daunorubicin analogues with deoxyribonucleic acid and their biological activity
5. Stereochemistry of intercalation: Interaction of daunorubicin with DNA
6. Cleavage of DNA by mammalian topoisomerase II
7. Adriamycin-induced DNA damage mediated by mammalian topoisomerase II
8. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals
9. Iron(III)-adriamycin and iron(III)-daunorubicin complexes: Physicochemical characteristics, interaction with DNA and antitumour activity
10. Effect of adriamycin on surface properties of sarcoma 180 ascites cells
11. Mechanism of adriamycin cardiotoxicity: Evidence for oxidative stress
12. Combined modality approach for high-risk breast cancer. The Milan Cancer Institute experience
13. Risk factors for doxorubicin-induced congestive heart failure
14. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with six months of cyclophosphamide, methotrexate and 5-fluorouracil in positive node breast cancer with tumours: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
15. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years
16. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
17. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
18. Improved disease free survival and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node positive primary breast cancer
19. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
20. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients
21. Early and delayed clinical cardiotoxicity of doxorubicin
22. Adriamycin (NSC-123127) cardiotoxicity: A clinicopathological correlation
23. Clinicopathologic analysis of adriamycin toxicity
24. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
25. Adjuvant cyclophosphamide, methotrexate and fluorouracil versus fluorouracil, epirubicin and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial
26. Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node positive breast cancer
27. Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity
28. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin
29. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up
30. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer
31. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group
32. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial
33. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer
34. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed dose doxorubicin
35. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
36. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane)
37. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
38. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
39. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicentre phase II trial
40. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
41. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99) given intraperitoneally to dogs
42. Reduced cardiotoxicity and preserved antitumour efficacy of liposome encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of cancer